



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3696

SERIAL NUMBER 10/766,181	FILING or 371(c) DATE 01/27/2004 RULE	CLASS 514	GROUP ART UNIT 1625	ATTORNEY DOCKET NO. 4-31321B	
APPLICANTS Guido Bold, Gipf-Oberfrick, SWITZERLAND; Paul William Manley, Arlesheim, SWITZERLAND; ** CONTINUING DATA ***** This application is a CON of 10/203,579 10/11/2002 PAT 6,706,731 which is a 371 of PCT/EP01/01331 02/07/2001 ** FOREIGN APPLICATIONS ***** SWITZERLAND 265/00 02/09/2000 ** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 06/16/2004					
Foreign Priority claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 35 USC 119(a-d) conditions met <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Verified and /ZINNA NORTHINGTON DAVIS/ Acknowledged Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials	STATE OR COUNTRY SWITZERLAND	SHEETS DRAWINGS 0	TOTAL CLAIMS 21	INDEPENDENT CLAIMS 1
ADDRESS NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES					
TITLE Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase					
FILING FEE RECEIVED 788	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		